Antidepressant drugs targeting on the histone deacetylase (HDAC) research progress

Abstract. Depression is a high incidence, low clinical cure rate, and high recurrence rates of mental disorders. Antidepressant drug development has been going on for several years, and is widely used in the market of monoamine oxidase inhibitors, for example, tricyclic antidepressants. There has been a lot of progress, but they still can't take effect immediately, and may cause adverse reactions or other defects in the patients nervous system and urinary system. At present, with the rapid development of global society, people are facing increasing mental stress, and the high incidence of depression is becoming increasingly severe. The development of antidepressant drugs is of urgency and importance. This article from the perspective of epigenetics, is based on the modification of histone acetylation, analysis of depression causes the histones to acetylate enzyme (HDAC), and targeted at HDAC drugs, mainly HDAC inhibitors (HDACi). This article reviews the therapeutic effects and therapeutic mechanisms of histone deacetylase (HDAC)-targeted drugs on depression, so as to provide a reference for exploring new treatment methods for depression.